Auspherix Raises £6 Million to Progress its Novel Antibiotics and Establishes UK Operations


03 June 2015

In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc (AIM IVO) led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).

The investment will be used to fund the Company’s drug discovery programme, expand the experienced management team and recruit a world-class microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a unique profile and novel mechanism of action, through lead optimization to final candidate selection within the next two years. Auspherix’s current lead compounds show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections.

The Company was co-founded by Professor Ian Charles and Dr Dagmar Alber during their time together at the ithree institute, UTS, Sydney. Dr Roberto Solari has joined the Board of Directors as its independent non-executive Chairman. Previously, Dr Solari was Vice President in GSK’s UK-based Respiratory Therapy Area, and is currently senior research fellow in the National Heart and Lung Institute, Imperial College London, focusing on respiratory infections. He is also an advisor to Imperial Innovations and Brandon Capital Partners, and is on the board of Heptares and the Science Advisory Board of Astex Pharmaceuticals. Before joining GSK, Dr Solari was CEO of the UK Medical Research Council’s technology transfer arm, MRCT, creating spin out companies such as Heptares and developing an internal drug discovery group. The Company has also appointed Grant Hawthorne, an experienced biotech company director as COO.

Founding venture investor and Auspherix Board member Dr Stephen Thompson, Partner at Brandon Capital Partners, the Australian venture capital firm that manages the MRCF, said: “Auspherix has progressed very rapidly and is now at the stage that building out the team is appropriate. The potential of the Company’s new class of anti-infectives is an extremely exciting opportunity and I am delighted that Imperial innovations has agreed to invest alongside the MRCF to move the programmes forward.”

Commenting on the investment and Auspherix’s potential, Dr Solari said: Auspherix’s novel chemistry has activity against a broad range of multidrug resistant (MDR) Gram-negative and Gram-positive bacterial infections and the initial pharmacokinetic profile of these compounds is consistent with their use as an antibacterial drug for a number of indications with high unmet need and large market potential.

”Professor Charles, co-founder and CSO said “The need to find new ways to combat infectious diseases becomes more urgent year-on-year as superbugs continue to emerge that are resistant to more and more current antibiotics. Whilst drug discovery is a long road, to have discovered antibacterial compounds with completely novel chemical structures is very exciting and I look forward to working with the new team as we move our discoveries forward towards the clinic.”The Company anticipates appointing a CEO within the coming months, and is building out its Stevenage-based R&D team. It will pursue a flexible investment and partnering model aimed at maximizing the speed with which it can develop and commercialize its novel antibiotic drug candidates.


Notes for editors:

About Auspherix Ltd

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multi drug resistant (MDR) important Gram negative and Gram-positive bacterial, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS$2 million in in Seed and Series A1 investments(2013-2014) from Australia’s Medical Research Commercialization Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO)).For further information please visit

About The Medical Research Commercialisation Fund (MRCF):

The MRCF Collaboration, managed by Brandon Capital Partners, brings together over 50 of Australia’s leading medical research institutes and research hospitals in an innovative investment collaboration. The MRCF provides dedicated investment funding to support the commercialization of early-stage medical research discoveries that originate from its members.AU$200m MRCF3 fund launched in 2015 is supported by Australian Super, Statewide Super, HESTA and HOSTPLUS industry superannuation funds. The MRCF’s first two funds, the MRCF Trust and MRCF IIF LP, total ling AU$ 51m were established in 2007 and 2011 and were supported by AustralianSuper, StatewideSuper and the Australian Government through its Innovation Investment Fund (IIF) program. The MRCF acknowledges support from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia For further information please visit and .

For more information please contact:

Media Relations – Instinctif Partners.

Auspherix In the UK

Dr Roberto Solari, Chairman

T: +44 (0)20 7594 3116

E: Roberto.solari@auspherix.comIn 

Australia Dr Stephen Thompson

 Director of Auspherix and Partner at Brandon Capital (manager of the MRCF)

T +61 (0)3 9657 0700E: